ABL Diagnostics Société anonyme
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
ABL Diagnostics Société anonyme (9BK0) - Net Assets
Latest net assets as of December 2024: €7.49 Million EUR
Based on the latest financial reports, ABL Diagnostics Société anonyme (9BK0) has net assets worth €7.49 Million EUR as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.81 Million) and total liabilities (€4.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.49 Million |
| % of Total Assets | 63.39% |
| Annual Growth Rate | 41.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 72.0 |
ABL Diagnostics Société anonyme - Net Assets Trend (2021–2024)
This chart illustrates how ABL Diagnostics Société anonyme's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ABL Diagnostics Société anonyme (2021–2024)
The table below shows the annual net assets of ABL Diagnostics Société anonyme from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.49 Million | +10.62% |
| 2023-12-31 | €6.77 Million | +0.20% |
| 2022-12-31 | €6.75 Million | +157.88% |
| 2021-12-31 | €2.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ABL Diagnostics Société anonyme's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1231.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.25 Million | 29.99% |
| Other Components | €5.24 Million | 70.01% |
| Total Equity | €7.49 Million | 100.00% |
ABL Diagnostics Société anonyme Competitors by Market Cap
The table below lists competitors of ABL Diagnostics Société anonyme ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KOMATSU (KOM1.SG)
STU:KOM1
|
$371.82K |
|
BORGWARNER
BE:BGW
|
$371.87K |
|
Jet.AI Inc.
NASDAQ:JTAI
|
$371.88K |
|
DBS GROUP HLDGS
MU:DEVL
|
$372.24K |
|
ROCKWOOL INT. -B- - Dusseldorf Stock Exchang
DU:R90
|
$371.52K |
|
Land & Homes Group Ltd
AU:LHM
|
$371.24K |
|
Hakken Capital Corp
V:HAKK-P
|
$370.95K |
|
Pacific Bay Minerals Ltd
PINK:PBMFF
|
$370.72K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABL Diagnostics Société anonyme's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,767,753 to 7,486,651, a change of 718,898 (10.6%).
- Net income of 285,170 contributed positively to equity growth.
- Other factors increased equity by 433,728.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €285.17K | +3.81% |
| Other Changes | €433.73K | +5.79% |
| Total Change | €- | 10.62% |
Book Value vs Market Value Analysis
This analysis compares ABL Diagnostics Société anonyme's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.28x to 6.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.31 | €2.98 | x |
| 2022-12-31 | €0.42 | €2.98 | x |
| 2023-12-31 | €0.42 | €2.98 | x |
| 2024-12-31 | €0.47 | €2.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABL Diagnostics Société anonyme utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.35%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.58x
- Recent ROE (3.81%) is below the historical average (7.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 9.85% | 0.00% | 0.00x | 1.04x | €-4.04K |
| 2022 | 16.37% | 12.64% | 0.57x | 2.28x | €430.25K |
| 2023 | 0.80% | 0.97% | 0.38x | 2.20x | €-622.41K |
| 2024 | 3.81% | 5.35% | 0.45x | 1.58x | €-463.50K |
Industry Comparison
This section compares ABL Diagnostics Société anonyme's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $2,007,386,767
- Average return on equity (ROE) among peers: -13.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABL Diagnostics Société anonyme (9BK0) | €7.49 Million | 9.85% | 0.58x | $371.65K |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $631.00 Million |
| DACHA STRATEGIC (7DC) | $40.24 Million | 0.65% | 0.08x | $81.97 Million |
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | $1.04 Billion | -33.28% | 0.39x | $47.71 Million |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| DocCheck AG (AJ91) | $18.14 Million | 3.32% | 0.15x | $18.00 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Tempus AI (F3M) | $-1.38 Billion | 0.00% | 0.00x | $4.75 Billion |
| Pangenomic Health Inc. (LL3) | $2.24 Million | -118.14% | 0.15x | $4.82 Million |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.89 Million |